|
PT3298033T
(pt)
|
2015-05-18 |
2020-09-22 |
Tcr2 Therapeutics Inc |
Composições e utilizações médicas para reprogramação de tcr utilizando proteínas de fusão
|
|
TWI773647B
(zh)
*
|
2015-06-23 |
2022-08-11 |
史隆凱特林紀念癌症中心 |
新穎pd-1免疫調控劑
|
|
CN108368170B
(zh)
|
2015-07-13 |
2022-04-15 |
西托姆克斯治疗公司 |
抗pd-1抗体、可活化抗pd-1抗体及其使用方法
|
|
KR102434314B1
(ko)
|
2015-09-01 |
2022-08-19 |
아게누스 인코포레이티드 |
항-pd-1 항체 및 이를 이용하는 방법
|
|
EA201890790A1
(ru)
|
2015-09-29 |
2018-10-31 |
Селджин Корпорейшн |
Связывающие pd-1 белки и способы их применения
|
|
PL3356411T3
(pl)
|
2015-10-02 |
2021-12-06 |
F. Hoffmann-La Roche Ag |
Przeciwciała dwuswoiste swoiste dla PD1 i TIM3
|
|
HUE057837T2
(hu)
|
2015-11-03 |
2022-06-28 |
Janssen Biotech Inc |
PD-1-et specifikusan kötõ ellenanyagok és alkalmazásaik
|
|
WO2017133175A1
(en)
*
|
2016-02-04 |
2017-08-10 |
Nanjing Legend Biotech Co., Ltd. |
Engineered mammalian cells for cancer therapy
|
|
EP3432924A1
(en)
|
2016-03-23 |
2019-01-30 |
Novartis AG |
Cell secreted minibodies and uses thereof
|
|
WO2017180587A2
(en)
|
2016-04-11 |
2017-10-19 |
Obsidian Therapeutics, Inc. |
Regulated biocircuit systems
|
|
WO2018053401A1
(en)
|
2016-09-19 |
2018-03-22 |
Celgene Corporation |
Methods of treating vitiligo using pd-1 binding proteins
|
|
JP2019531284A
(ja)
|
2016-09-19 |
2019-10-31 |
セルジーン コーポレイション |
Ｐｄ−１結合タンパク質を使用して免疫障害を治療する方法
|
|
EP3544996A2
(en)
|
2016-11-22 |
2019-10-02 |
TCR2 Therapeutics Inc. |
Compositions and methods for tcr reprogramming using fusion proteins
|
|
WO2018106864A1
(en)
|
2016-12-07 |
2018-06-14 |
Agenus Inc. |
Antibodies and methods of use thereof
|
|
JP6430682B2
(ja)
*
|
2016-12-19 |
2018-11-28 |
昭和電工株式会社 |
レドックスフロー電池の運転方法
|
|
AU2018234810B2
(en)
|
2017-03-15 |
2023-05-11 |
Pandion Operations, Inc. |
Targeted immunotolerance
|
|
EP3606946B1
(en)
|
2017-04-03 |
2022-08-24 |
F. Hoffmann-La Roche AG |
Immunoconjugates of an anti-pd-1 antibody with a mutant il-2 or with il-15
|
|
DK3606954T3
(en)
*
|
2017-04-05 |
2022-09-26 |
Hoffmann La Roche |
Anti-LAG3-antistoffer
|
|
IL268527B2
(en)
|
2017-04-05 |
2024-03-01 |
Hoffmann La Roche |
Bispecific antibodies specifically binding to pd1 and lag3
|
|
WO2018195348A1
(en)
*
|
2017-04-19 |
2018-10-25 |
University Of Southern California |
Compositions and methods for treating cancer
|
|
US11965021B2
(en)
|
2017-04-26 |
2024-04-23 |
Eureka Therapeutics, Inc. |
Cells expressing chimeric activating receptors and chimeric stimulating receptors and uses thereof
|
|
US11427636B2
(en)
|
2017-05-01 |
2022-08-30 |
The Children's Medical Center Corporation |
Methods and compositions relating to anti-PD1 antibody reagents
|
|
US10676516B2
(en)
|
2017-05-24 |
2020-06-09 |
Pandion Therapeutics, Inc. |
Targeted immunotolerance
|
|
CN111094350B
(zh)
*
|
2017-07-06 |
2024-09-03 |
美勒斯公司 |
调节由细胞表达的生物活性的抗体
|
|
WO2019018727A1
(en)
*
|
2017-07-21 |
2019-01-24 |
Washington University |
METHODS AND COMPOSITIONS FOR T-CELL ACTIVATION
|
|
PE20200850A1
(es)
|
2017-11-01 |
2020-08-20 |
Juno Therapeutics Inc |
Receptores de antigenos quimericos especificos para el antigeno de maduracion de celulas b y polinucleotidos que codifican los mismos
|
|
US10174092B1
(en)
|
2017-12-06 |
2019-01-08 |
Pandion Therapeutics, Inc. |
IL-2 muteins
|
|
US10946068B2
(en)
|
2017-12-06 |
2021-03-16 |
Pandion Operations, Inc. |
IL-2 muteins and uses thereof
|
|
US12398209B2
(en)
|
2018-01-22 |
2025-08-26 |
Janssen Biotech, Inc. |
Methods of treating cancers with antagonistic anti-PD-1 antibodies
|
|
US20210069246A1
(en)
*
|
2018-01-31 |
2021-03-11 |
Celgene Corporation |
Combination therapy using adoptive cell therapy and checkpoint inhibitor
|
|
EP3752601A4
(en)
|
2018-02-15 |
2022-03-23 |
Memorial Sloan-Kettering Cancer Center |
FOXP3-TARGETING AGENT COMPOSITIONS AND METHODS OF USE FOR ADOPTIVE CELL THERAPY
|
|
AR114127A1
(es)
|
2018-03-02 |
2020-07-22 |
Lilly Co Eli |
Anticuerpos agonistas contra pd-1 y usos de estos
|
|
JP7466459B2
(ja)
|
2018-04-17 |
2024-04-12 |
セルデックス セラピューティクス インコーポレイテッド |
抗ｃｄ２７および抗ｐｄ－ｌ１抗体ならびに二重特異性構築物
|
|
SG11202101067XA
(en)
*
|
2018-07-04 |
2021-03-30 |
Cytoimmune Therapeutics Inc |
Compositions and methods for immunotherapy targeting flt3, pd-1, and/or pd-l1
|
|
US12263190B2
(en)
|
2018-11-08 |
2025-04-01 |
Juno Therapeutics, Inc. |
Methods and combinations for treatment and T cell modulation
|
|
CN111320690B
(zh)
*
|
2018-12-17 |
2022-04-05 |
程联胜 |
一种抗人Tim3单克隆抗体及其应用
|
|
CN111748580B
(zh)
*
|
2019-03-28 |
2022-09-13 |
百奥泰生物制药股份有限公司 |
一种检测免疫检查点抗体活性的方法
|
|
CN111892655B
(zh)
*
|
2019-05-06 |
2022-10-28 |
四川大学 |
抗pd-1纳米抗体的筛选及应用
|
|
US11739146B2
(en)
|
2019-05-20 |
2023-08-29 |
Pandion Operations, Inc. |
MAdCAM targeted immunotolerance
|
|
US20220275088A1
(en)
*
|
2019-06-14 |
2022-09-01 |
Dana-Farber Cancer Institute, Inc. |
Antibodies against pd-1 and methods of use thereof
|
|
KR20220030956A
(ko)
|
2019-07-05 |
2022-03-11 |
오노 야꾸힝 고교 가부시키가이샤 |
Pd-1/cd3 이중 특이성 단백질에 의한 혈액암 치료
|
|
WO2021011480A1
(en)
*
|
2019-07-12 |
2021-01-21 |
The Research Foundation For The State University Of New York |
Compositions and methods to block and bind cxcr4 to modulate cellular function
|
|
JP7771749B2
(ja)
|
2019-08-08 |
2025-11-18 |
小野薬品工業株式会社 |
二重特異性タンパク質
|
|
US20220289862A1
(en)
*
|
2019-08-16 |
2022-09-15 |
H. Lee Moffitt Cancer Center And Research Institute, Inc. |
Anti-cd83 chimeric antigen receptor expressing t regulatory cells
|
|
CN112852740A
(zh)
*
|
2019-11-27 |
2021-05-28 |
深圳市菲鹏生物治疗股份有限公司 |
Car-t细胞和检测方法
|
|
US11981715B2
(en)
|
2020-02-21 |
2024-05-14 |
Pandion Operations, Inc. |
Tissue targeted immunotolerance with a CD39 effector
|
|
HUE069403T2
(hu)
|
2020-05-26 |
2025-03-28 |
Boehringer Ingelheim Int |
Anti-PD-1 antitestek
|
|
CN114437229B
(zh)
*
|
2020-11-01 |
2024-03-12 |
复旦大学 |
携带pd-1単链抗体且靶向egfr抗原的car t免疫细胞的制备及其用途
|
|
CN112812174A
(zh)
*
|
2021-01-15 |
2021-05-18 |
新乡学院 |
猪pd-l14qn-af表位多肽及其应用
|
|
CN115521378B
(zh)
*
|
2021-07-23 |
2023-12-22 |
南京吉盛澳玛生物医药有限公司 |
Pd-l1抗体及其用途
|
|
WO2024182754A2
(en)
*
|
2023-03-02 |
2024-09-06 |
Fred Hutchinson Cancer Center |
Anti-pd-1 chimeric antigen receptor t cells and therapeutic uses thereof
|
|
WO2025059162A1
(en)
|
2023-09-11 |
2025-03-20 |
Dana-Farber Cancer Institute, Inc. |
Car-engager containing il-2 variants to enhance the functionality of car t cells
|
|
WO2025085538A1
(en)
*
|
2023-10-17 |
2025-04-24 |
Lanier Biotherapeutics, Inc. |
Alarmin binding molecules and treatment of cancer
|